Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2024-518174-13-00Phase 3Completed
Phase 3, randomised, single-blind trial in hepatic disease comparing Custodiol-N with Custodiol (2 arms). Primary endpoint: Area under the curve of alanine aminotransferase during the first 7 days after transplantation. Started Oct 2024; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2024-518174-13-00.